Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Assess VPM1002 in Reducing Healthcare Professionals' Absenteeism in COVID-19 Pandemic

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04387409
Recruitment Status : Recruiting
First Posted : May 13, 2020
Last Update Posted : June 16, 2020
Sponsor:
Collaborator:
FGK Clinical Research GmbH
Information provided by (Responsible Party):
Vakzine Projekt Management GmbH

Tracking Information
First Submitted Date  ICMJE May 11, 2020
First Posted Date  ICMJE May 13, 2020
Last Update Posted Date June 16, 2020
Actual Study Start Date  ICMJE May 25, 2020
Estimated Primary Completion Date June 30, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 11, 2020)
Number of days absent from work due to respiratory disease (with or without documented SARS-CoV-2 infection) [ Time Frame: From day 0 to day 240 ]
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: May 11, 2020)
  • Cumulative incidence of documented SARS-CoV-2 infection [ Time Frame: From day 0 to day 240 ]
  • Number of days absent from work due to documented SARS-CoV-2 infection [ Time Frame: From day 0 to day 240 ]
  • Number of days absent from work due to exposure to person with documented SARS-CoV-2 infection [ Time Frame: From day 0 to day 240 ]
  • Number of days absent from work due to symptoms of respiratory disease, documented SARS-CoV-2 infection, or fever (≥ 38 °C) [ Time Frame: From day 0 to day 240 ]
  • Number of days of self-reported fever (≥ 38 °C) [ Time Frame: From day 0 to day 240 ]
  • Number of days of self-reported acute respiratory symptoms [ Time Frame: From day 0 to day 240 ]
  • Cumulative incidence of self-reported acute respiratory symptoms [ Time Frame: From day 0 to day 240 ]
  • Cumulative incidence of death for any reason [ Time Frame: From day 0 to day 240 ]
  • Cumulative incidence of death due to documented SARS-CoV-2 infection [ Time Frame: From day 0 to day 240 ]
  • Cumulative incidence of ICU admission for any reason [ Time Frame: From day 0 to day 240 ]
  • Cumulative incidence of ICU admission due to documented SARS-CoV-2 infection [ Time Frame: From day 0 to day 240 ]
  • Cumulative incidence of hospital admission for any reason [ Time Frame: From day 0 to day 240 ]
  • Cumulative incidence of hospital admission due to documented SARS-CoV-2 infection [ Time Frame: From day 0 to day 240 ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Study to Assess VPM1002 in Reducing Healthcare Professionals' Absenteeism in COVID-19 Pandemic
Official Title  ICMJE A Phase III, Double-blind, Randomized, Placebo-controlled Multicentre Clinical Trial to Assess the Efficacy and Safety of VPM1002 in Reducing Healthcare Professionals' Absenteeism in the SARS-CoV-2 Pandemic by Modulating the Immune System
Brief Summary

The aim of this study is to investigate whether vaccination of healthcare professionals with VPM1002 could reduce the number of days absent from work due to respiratory disease (with or without documented SARS-CoV-2 infection).

VPM1002 is a vaccine that is a further development of the old Bacillus Calmette-Guérin (BCG) vaccine, which has been used successfully as a vaccine against tuberculosis for about 100 years, especially in developing countries. VPM1002 has been shown in various clinical studies to be significantly safer than the BCG vaccine.

VPM1002 strengthens the body's immune defence and vaccination with BCG reduces the frequency of respiratory diseases. It is therefore assumed that a VPM1002 vaccination could also provide (partial) protection against COVID-19 disease caused by the new corona virus "SARS-CoV 2".

A total of 1200 health care professionals (doctors, nurses and paramedical staff) with high expected exposure to SARSCoV-2 infected patients will receive a single dose of either VPM1002 or Placebo. All subjects will be requested to enter data regarding absenteeism, adverse events / serious adverse events, hospitalizations, intensive care unit admissions into an online questionnaire.

Detailed Description

Based on the evidence that BCG vaccine

  1. can potentiate immune responses to other vaccines through induction of trained innate immunity and heterologous adaptive immunity and
  2. can reduce the incidence of respiratory infections, exert antiviral effects in experimental models, and reduce viremia in an experimental human model of viral infection,

it is hypothesized that BCG vaccination may induce (partial) protection against the susceptibility to and/or severity of SARS- CoV-2 infection.

VPM1002 is being developed with the aim to replace BCG by a vaccine that has a better safety profile and superior efficacy. Evidence from pre-clinical and clinical studies demonstrate that VPM1002 is safer and is more immunogenic than the existing BCG vaccine. It is therefore anticipated that VPM1002 will also perform better in reducing the severity of the symptoms of an infection with the SARS CoV-2 than the BCG vaccine. Further, manufacturing of VPM1002 using state-of-the-art production methods will help hasten the production of millions of doses in a very short time and thus would be beneficial in the current SARS-CoV-2 pandemic situation.

The current trial will assess the efficacy and safety of VPM1002 to reduce health care professionals ' absenteeism in the SARS-CoV-2 pandemic by modulating the immune system.

A total of 1200 health care professionals (doctors, nurses and paramedical staff) with high expected exposure to SARSCoV-2 infected patients (e.g. those employed in emergency departments, intensive care unit, infectious disease ward, COVID-19 isolation wards, respiratory wards, etc.) will be enrolled, across hospitals in Germany. Informed consent will be obtained from the subjects willing to take part in the trial. This will be followed by assessment of the eligibility criteria. Subjects who fulfil the inclusion/exclusion criteria will be centrally randomized in a 1:1 ratio to receive a single dose of either VPM1002 or Placebo.

All subjects will be requested to sign into a web-based tool designed for this trial. All subjects will be followed-up entirely remotely. The web-based questionnaires will be designed to collect data regarding absenteeism, adverse events / serious adverse events, hospitalizations, intensive care unit admissions and other secondary endpoints. The investigators will review the outcome and safety data.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Subjects who fulfil the inclusion/exclusion criteria will be centrally randomized in a 1:1 ratio to receive a single dose (0.1 ml) of either VPM1002 or Placebo.
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Masking Description:
The reconstitution and administration of trial intervention will be done by unblinded site personnel who will not be involved in the collection or evaluation of outcome data.
Primary Purpose: Prevention
Condition  ICMJE Infection, Respiratory Tract
Intervention  ICMJE
  • Biological: VPM1002
    The investigational product will be administered via intradermal injection with a 1.0-ml syringe, sub-graduated into hundredths of ml (1/100 ml), and fitted with a short bevel needle (25G/0.50 mm or 26G/0.45 mm, 10 mm in length).
  • Biological: Placebo
    The investigational product will be administered via intradermal injection with a 1.0-ml syringe, sub-graduated into hundredths of ml (1/100 ml), and fitted with a short bevel needle (25G/0.50 mm or 26G/0.45 mm, 10 mm in length).
Study Arms  ICMJE
  • Active Comparator: VPM1002

    The active ingredient of the recombinant BCG vaccine, VPM1002, is Mycobacterium bovis rBCGΔureC::hly, freeze-dried and standardized to the number of viable mycobacteria (colony forming units; CFU) per application.

    Dose: 2-8 x 10e5 CFU VPM1002 administered in 0.1 ml reconstituted suspension.

    Intervention: Biological: VPM1002
  • Placebo Comparator: Placebo
    Physiological saline 0.1ml
    Intervention: Biological: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: May 11, 2020)
1200
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE June 30, 2021
Estimated Primary Completion Date June 30, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Adult (≥18 years)
  • Male or female
  • Hospital personnel with expected high SARS-CoV-2 exposure
  • Subject is contractually capable, able to understand information on study and has signed informed consent sheet
  • Subject has access to an internet-enabled electronic device
  • Women of childbearing potential who are currently using reliable methods of birth control, have a negative pregnancy test during screening and have no intention to become pregnant for at least 3 months post-vaccination.

Exclusion Criteria:

  • Known hypersensitivity or allergy to (components of) the VPM1002 vaccine or serious adverse reactions to prior BCG administration
  • Known active or latent Mycobacterium tuberculosis infection or with another mycobacterial species. A history with or suspicion of M. tuberculosis infection.
  • Fever (>38 °C) within the past 24 hours
  • Pregnant or breast-feeding
  • Suspicion of active viral or bacterial infection
  • Participation of subject in another study within 30 days before screening and during this study
  • Person is an employee of the sponsor, a relative of the investigator or in direct reporting line to clinical trial staff at the clinical trial site
  • Severely immunocompromised subjects, such as:

    1. subjects with known infection with the human immunodeficiency virus (HIV);
    2. subjects with solid organ transplantation;
    3. subjects with bone marrow transplantation;
    4. subjects under chemotherapy, immunotherapy and radiotherapy;
    5. subjects with primary immunodeficiency;
    6. treatment with any anti-cytokine therapies;
    7. treatment with oral or intravenous steroids defined as daily doses of 10 mg prednisone or equivalent for longer than 3 months
  • Active solid or non-solid malignancy or lymphoma in the past 5 years
  • Direct involvement in the design or the execution of the present clinical trial
  • Expected absence from work of ≥4 of the following 12 weeks due to any reason (holidays, maternity leave, retirement, planned surgery etc)
  • Employed to the hospital < 22 hours per week
  • Previous positive SARS-CoV-2 test result
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE
Contact: Leander Grode, Dr rer nat +49511169908 ext 14 grode@vakzine-manager.de
Listed Location Countries  ICMJE Germany
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04387409
Other Study ID Numbers  ICMJE VPM1002-DE-3.06CoV
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Plan Description: There is uncertainty whether the European Union General Data Protection Regulation allows dissemination of individual participant data to other researchers. Some reasons why the EU Regulation would not allow this are the lack of suitable safeguards when person data are transferred to any researcher asking for it and the impairment of the rights of the subjects for erasure of their data once they are disseminated.
Responsible Party Vakzine Projekt Management GmbH
Study Sponsor  ICMJE Vakzine Projekt Management GmbH
Collaborators  ICMJE FGK Clinical Research GmbH
Investigators  ICMJE
Study Director: Leander Grode, Dr rer nat Vakzine Projekt Management GmbH
PRS Account Vakzine Projekt Management GmbH
Verification Date June 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP